Connect with us

Hi, what are you looking for?

Jewish Business News

IPOs

Ophthalix Files Preliminary Prospectus in New York for IPO

Can-Fite Eye Disease spin-off hopes to raise up to US$10 million on NYSE. Road show starts in July. 

 –

rsz_220_220_pnina-Fishman220

Can-Fite CEO Pnina Fishman

/ By Gali Weinreb /

Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board: CANFY) spinoff OphthaliX Inc. (Bulletin Board: OPLI), which is developing treatments for eye diseases, has filed a prospectus with the US Securities and Exchange Commission (SEC) to raise up to $10 million in an IPO on the New York Stock Exchange. No pricing terms were disclosed.

Sources inform ”Globes” that OphthaliX will begin its road show in late July.
OphthaliX is conducting a Phase III clinical trial for its treatment for dry-eye syndrome. The anti-inflammatory drug is based on the same molecule developed by Can-Fite for the treatment of psoriasis and rheumatism. Studies by Can-Fite found that the drug alleviated the symptoms of dry-eye syndrome.

Can-Fite therefore decided to spin off its ophthalmic activity, and to transfer the more advanced product to the new company, which merged with a company listed on the Bulletin Board. OphthaliX’s executives and directors come from the ophthalmic field and are familiar with the US capital market.

OphthaliX has a market cap of $69 million, after losing half its value in the past year. It still has a higher market cap than the NIS 120 million ($32.5 million) market cap for Can-Fite, which owns 82% of OphthaliX.
Published by www.globes-online.com 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış